These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37372371)

  • 1. The Distribution of the Genotypes of
    Abdrakhmanov A; Akilzhanova A; Shaimerdinova A; Zhalbinova M; Tuyakova G; Abildinova S; Albayev R; Ainabekova B; Chinybayeva A; Suleimen Z; Bekbossynova M
    Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
    Ji Q; Zhang C; Xu Q; Wang Z; Li X; Lv Q
    Br J Clin Pharmacol; 2021 May; 87(5):2247-2255. PubMed ID: 33179295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation.
    Zhu Z; Qian C; Su C; Tao H; Mao J; Guo Z; Zhu X; Pan J
    BMC Cardiovasc Disord; 2022 Nov; 22(1):481. PubMed ID: 36368930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants of
    Abdrakhmanov A; Zholdybayeva E; Shaimerdinova A; Kulmambetova G; Abildinova S; Albayev R; Tuyakova G; Rib E; Suleimen Z; Abdrakhmanova Z; Bekbossynova M
    Caspian J Intern Med; 2024; 15(3):499-508. PubMed ID: 39011438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of dabigatran etexilate interindividual variability.
    Dimatteo C; D'Andrea G; Vecchione G; Paoletti O; Cappucci F; Tiscia GL; Buono M; Grandone E; Testa S; Margaglione M
    Thromb Res; 2016 Aug; 144():1-5. PubMed ID: 27261537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
    Sychev D; Skripka A; Ryzhikova K; Bochkov P; Shevchenko R; Krupenin P; Ivashchenko D; Kogay V; Listratov A; Krainyaya A; Gurinovich O; Sokolova A; Napalkov D; Fomin V
    Drug Metab Pers Ther; 2020 Mar; 35(1):. PubMed ID: 32134727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of ABCB1 and CES1 Polymorphisms on Plasma Levels of Dabigatran and Risk of Hemorrhagic Complications in Ischemic Stroke Patients.
    Olšerová A; Janský P; Magerová H; Šrámková T; Kešnerová P; Kmetonyová S; Šulc V; Halmová H; Šrámek M; Šarbochová I; Paulasová-Schwabová J; Benešová K; Macek J; Maťoška V; Tomek A
    Am J Ther; 2024 Jul-Aug 01; 31(4):e362-e371. PubMed ID: 38525959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of
    Cumitini L; Renda G; Giordano M; Rolla R; Shail T; Sacchetti S; Iezzi L; Giacomini L; Zanotti V; Auciello R; Angilletta I; Foglietta M; Zucchelli M; Antonucci I; Stuppia L; Gallina S; Dianzani U; Patti G
    J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731074
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of
    Sychev DA; Levanov AN; Shelekhova TV; Bochkov PO; Denisenko NP; Ryzhikova KA; Mirzaev KB; Grishina EA; Gavrilov MA; Ramenskaya GV; Kozlov AV; Bogoslovsky T
    Pharmgenomics Pers Med; 2018; 11():127-137. PubMed ID: 30100750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report.
    Wu T; Xia X; Fu J; Chen W; Zhang J
    Medicine (Baltimore); 2020 Sep; 99(36):e22084. PubMed ID: 32899083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
    Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
    Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects.
    Liu Y; Yang C; Qi W; Pei Z; Xue W; Zhu H; Dong M; Guo Y; Cong D; Wang F
    Pharmgenomics Pers Med; 2021; 14():477-485. PubMed ID: 33935512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review.
    Raymond J; Imbert L; Cousin T; Duflot T; Varin R; Wils J; Lamoureux F
    J Pers Med; 2021 Jan; 11(1):. PubMed ID: 33440670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation.
    Sychev D; Ostroumova O; Cherniaeva M; Shakhgildian N; Mirzaev K; Abdullaev S; Denisenko N; Sozaeva Z; Kachanova A; Gorbatenkova S; Shastina V
    High Blood Press Cardiovasc Prev; 2022 Sep; 29(5):469-480. PubMed ID: 35960493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation.
    Wu T; Wu S; Li L; Xiang J; Wang N; Chen W; Zhang J
    Hum Genomics; 2023 Jul; 17(1):59. PubMed ID: 37420302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran.
    Zubiaur P; Saiz-Rodríguez M; Ochoa D; Navares-Gómez M; Mejía G; Román M; Koller D; Soria-Chacartegui P; Almenara S; Abad-Santos F
    Adv Ther; 2020 Aug; 37(8):3537-3550. PubMed ID: 32564268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.
    Roşian AN; Roşian ŞH; Kiss B; Ştefan MG; Trifa AP; Ober CD; Anchidin O; Buzoianu AD
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32316515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of ABCB1 gene polymorphisms rs1128503, rs2032582, rs4148738 with anemia in patients receiving dabigatran after total knee arthroplasty.
    Kasimova A; Labutin D; Gvozdetsky A; Bozhkova S
    Chin J Traumatol; 2024 Jan; 27(1):27-33. PubMed ID: 37423837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.
    Sychev DA; Sokolov AV; Reshetko OV; Fisenko VP; Sychev IN; Grishina EA; Bochkov PO; Shevchenko RV; Abdullaev SP; Denisenko NP; Ivashchenko DV; Sozaeva ZA; Kachanova AA
    Pharmacogenet Genomics; 2022 Dec; 32(9):301-307. PubMed ID: 36256705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic determinants of dabigatran plasma levels and their relation to bleeding.
    Paré G; Eriksson N; Lehr T; Connolly S; Eikelboom J; Ezekowitz MD; Axelsson T; Haertter S; Oldgren J; Reilly P; Siegbahn A; Syvanen AC; Wadelius C; Wadelius M; Zimdahl-Gelling H; Yusuf S; Wallentin L
    Circulation; 2013 Apr; 127(13):1404-12. PubMed ID: 23467860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.